HRP20090527T1 - Nogo-a neutralising immunoglobulins for treatment of neurological diseases - Google Patents

Nogo-a neutralising immunoglobulins for treatment of neurological diseases

Info

Publication number
HRP20090527T1
HRP20090527T1 HR20090527T HRP20090527T HRP20090527T1 HR P20090527 T1 HRP20090527 T1 HR P20090527T1 HR 20090527 T HR20090527 T HR 20090527T HR P20090527 T HRP20090527 T HR P20090527T HR P20090527 T1 HRP20090527 T1 HR P20090527T1
Authority
HR
Croatia
Prior art keywords
nogo
neutralising
immunoglobulins
treatment
neurological diseases
Prior art date
Application number
HR20090527T
Other languages
English (en)
Croatian (hr)
Inventor
Henry Ellis Jonathan
Eon-Duval Alexandre
Ian Grundy Robert
Hussain Farhana
Mcadam Ruth
Plumpton Christopher
Kumar Prinjha Rabinder
Alexander Wilson Paul
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0329684A external-priority patent/GB0329684D0/en
Priority claimed from GB0329711A external-priority patent/GB0329711D0/en
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of HRP20090527T1 publication Critical patent/HRP20090527T1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HR20090527T 2003-12-22 2009-10-01 Nogo-a neutralising immunoglobulins for treatment of neurological diseases HRP20090527T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0329684A GB0329684D0 (en) 2003-12-22 2003-12-22 Method
GB0329711A GB0329711D0 (en) 2003-12-22 2003-12-22 Antibodies
PCT/GB2004/005325 WO2005061544A2 (en) 2003-12-22 2004-12-20 Nogo-a neutralising immunoglobulins for treatment of neurological diseases

Publications (1)

Publication Number Publication Date
HRP20090527T1 true HRP20090527T1 (en) 2009-11-30

Family

ID=34712703

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20090527T HRP20090527T1 (en) 2003-12-22 2009-10-01 Nogo-a neutralising immunoglobulins for treatment of neurological diseases

Country Status (28)

Country Link
US (4) US7988964B2 (xx)
EP (3) EP2213684A3 (xx)
JP (2) JP4901480B2 (xx)
KR (1) KR101150548B1 (xx)
AR (1) AR048912A1 (xx)
AT (1) ATE440866T1 (xx)
AU (1) AU2004303585B2 (xx)
BR (1) BRPI0417959A (xx)
CA (1) CA2549956C (xx)
CY (1) CY1110530T1 (xx)
DE (1) DE602004022871D1 (xx)
DK (1) DK1711530T3 (xx)
ES (1) ES2330444T3 (xx)
HK (1) HK1100144A1 (xx)
HR (1) HRP20090527T1 (xx)
IL (1) IL176206A (xx)
IS (1) IS2739B (xx)
MA (1) MA28289A1 (xx)
MX (1) MXPA06007190A (xx)
MY (1) MY144612A (xx)
NO (1) NO20062767L (xx)
NZ (1) NZ548013A (xx)
PL (1) PL1711530T3 (xx)
PT (1) PT1711530E (xx)
RU (1) RU2362780C2 (xx)
SI (1) SI1711530T1 (xx)
TW (1) TWI329649B (xx)
WO (2) WO2005061544A2 (xx)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2390425T3 (es) 2000-12-22 2012-11-12 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Uso de moléculas de orientación repulsivas (RGM) y sus moduladores
GB0228832D0 (en) * 2002-12-10 2003-01-15 Novartis Ag Organic compound
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
GB0321997D0 (en) * 2003-09-19 2003-10-22 Novartis Ag Organic compound
BRPI0417959A (pt) 2003-12-22 2007-03-27 Glaxo Group Ltd anticorpo ou fragmento funcional deste, composição farmcêutica, método para tratamento ou profilaxia de acidente vascular cerebral e outras doenças/distúrbios neurológicos em um ser humano, uso de um anticorpo anti-nogo, e, métodos para inibir a neurodegeneração e/ou promover a recuperação funcional em um paciente humano, para promover o crescimento axonal, para produzir um anticorpo anti-nogo e para produzir uma composição farmacêutica intravenosamente administrável
NZ564567A (en) * 2005-07-05 2010-09-30 Glaxo Group Ltd Humanised antibodies specific for neurite outgrowth inhibitor-A and pharmaceutical uses thereof
EP1928905B1 (de) 2005-09-30 2015-04-15 AbbVie Deutschland GmbH & Co KG Bindungsdomänen von proteinen der repulsive guidance molecule (rgm) proteinfamilie und funktionale fragmente davon sowie deren verwendung
KR20140087058A (ko) 2005-11-30 2014-07-08 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
PT2289909E (pt) 2005-11-30 2015-02-10 Abbvie Inc Método de rastreio, processo de purificação de globulómeros a-beta não difundíveis, anticorpos selectivos contra os referidos globulómeros a-beta não difundíveis e processo para o fabrico dos referidos anticorpos
GB0525662D0 (en) * 2005-12-16 2006-01-25 Glaxo Group Ltd Immunoglobulins
US8663635B2 (en) 2006-03-21 2014-03-04 The Regents Of The University Of California N-cadherin: target for cancer diagnosis and therapy
US20090291976A1 (en) * 2006-06-27 2009-11-26 Peter Andrew Ferchmin Neuronal circuit-dependent neuroprotection by interaction between nicotinic receptors
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
ES2435437T3 (es) * 2006-12-07 2013-12-19 Novartis Ag Anticuerpos antagonistas contra Ephb3
US20100311767A1 (en) * 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
WO2009026117A2 (en) * 2007-08-16 2009-02-26 Glaxo Group Limited Novel compounds
ES2425768T3 (es) * 2007-11-02 2013-10-17 Novartis Ag Moléculas de unión a nogo-a mejoradas y uso farmacéutico de las mismas
US8962803B2 (en) * 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
JP2011521619A (ja) * 2008-04-04 2011-07-28 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 腫瘍成長、血管新生および転移を妨害する癌標的に対する新規抗体
WO2010004031A2 (en) * 2008-07-11 2010-01-14 Glaxo Group Limited Novel treatment
US10266585B2 (en) 2009-08-28 2019-04-23 The Board Of Regents Of The Univerity Of Texas System Methods of treating brain injury
JP5951498B2 (ja) 2009-12-08 2016-07-13 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー 網膜神経線維層変性の治療に使用するためのｒｇｍａタンパク質に対するモノクローナル抗体
ES2684475T3 (es) 2010-04-15 2018-10-03 Abbvie Inc. Proteínas que se unen a beta amiloide
WO2012004773A1 (en) 2010-07-09 2012-01-12 Universite De Geneve New uses of nogo-a inhibitors and related methods
MX358739B (es) 2010-08-14 2018-09-03 Abbvie Inc Star Proteinas de union a amiloide beta.
CA2817973C (en) * 2010-10-15 2019-06-25 The Board Of Regents Of The University Of Texas System Antibodies that bind amyloid oligomers
EA201390472A1 (ru) 2010-10-29 2014-02-28 Иммьюноджен, Инк. Новые молекулы, связывающиеся с egfr, и их иммуноконъюгаты
BR112013010569A2 (pt) 2010-10-29 2017-07-04 Immunogen Inc moléculas de ligação de egfr não antagonísticas e imunoconjugados das mesma
AU2012340686A1 (en) 2011-11-21 2014-06-19 Immunogen, Inc. Method of treatment of tumors that are resistant to EGFR therapies by EGFR antibody cytotoxic agent conjugate
JP6684490B2 (ja) * 2012-01-09 2020-04-22 ザ・スクリップス・リサーチ・インスティテュート 超長相補性決定領域及びその使用
PE20142168A1 (es) 2012-01-27 2015-01-17 AbbVie Deutschland GmbH and Co KG Composicion y metodo para el diagnostico y el tratamiento de las enfermedades asociadas a la degeneracion de las neuritas
CA2876284A1 (en) 2012-07-05 2014-01-09 Glaxo Group Limited Optimum dose regime of an anti-nogo-a antibody in the treatment of amyotrophic lateral sclerosis
EA201792414A1 (ru) 2015-05-04 2018-06-29 Сайтомкс Терапьютикс, Инк. Антитела против cd166, активируемые антитела против cd166 и способы их применения
US20180362660A1 (en) * 2016-05-09 2018-12-20 Schickwann Tsai Anti-penumbra monoclonal antibodies for detection and therapy of normal and abnormal B lymphocytes
JP2020531045A (ja) * 2017-07-14 2020-11-05 シートムエックス セラピューティクス，インコーポレイテッド 抗ｃｄ１６６抗体およびその使用
US20210292413A1 (en) * 2018-09-25 2021-09-23 Academia Sinica Anti-siglec antibody, pharmaceutical composition comprising the same, and uses thereof
KR20220087516A (ko) 2019-10-24 2022-06-24 노바고 테라퓨틱스 아게 신규 항-Nogo-A 항체
CN116635718A (zh) * 2020-12-02 2023-08-22 安捷伦科技有限公司 用于在免疫组织化学（ihc）方案中使用以诊断癌症的抗人cd10抗体
WO2024041450A1 (zh) * 2022-08-22 2024-02-29 舒泰神（北京）生物制药股份有限公司 特异性识别Nogo-A的抗体及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3935074A (en) * 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
EP0940391B1 (en) 1994-05-27 2004-08-18 GlaxoSmithKline S.p.A. Quinoline derivatives as tachykinin NK3 receptor antagonists
CZ304224B6 (cs) * 1998-11-06 2014-01-15 Schwab Monoklonální protilátka
FR2792199B3 (fr) 1999-04-13 2001-05-18 Sanofi Sa Utilisation de l'osanetant pour la preparation de medicaments utiles dans le traitement des troubles de l'humeur
US20030113891A1 (en) * 2000-02-11 2003-06-19 Lawrence Blatt Method and reagent for the inhibition of NOGO and NOGO receptor genes
GB0101313D0 (en) * 2001-01-18 2001-02-28 Glaxo Group Ltd Assay
AU2003223330A1 (en) * 2002-04-17 2003-11-03 Pharmacia And Upjohn Company Llc Compositions and method of treating alzheimer's disease
GB0228832D0 (en) * 2002-12-10 2003-01-15 Novartis Ag Organic compound
EA009643B1 (ru) * 2003-04-16 2008-02-28 Йейл Юниверсити Лечение состояний, включающих амилоидные бляшки
GB0318727D0 (en) 2003-08-08 2003-09-10 Smithkline Beecham Corp Novel compounds
GB0321997D0 (en) * 2003-09-19 2003-10-22 Novartis Ag Organic compound
BRPI0417959A (pt) 2003-12-22 2007-03-27 Glaxo Group Ltd anticorpo ou fragmento funcional deste, composição farmcêutica, método para tratamento ou profilaxia de acidente vascular cerebral e outras doenças/distúrbios neurológicos em um ser humano, uso de um anticorpo anti-nogo, e, métodos para inibir a neurodegeneração e/ou promover a recuperação funcional em um paciente humano, para promover o crescimento axonal, para produzir um anticorpo anti-nogo e para produzir uma composição farmacêutica intravenosamente administrável

Also Published As

Publication number Publication date
PT1711530E (pt) 2009-10-22
EP1706426A2 (en) 2006-10-04
MY144612A (en) 2011-10-14
US20140147435A1 (en) 2014-05-29
WO2005061545A2 (en) 2005-07-07
US20060029603A1 (en) 2006-02-09
TWI329649B (en) 2010-09-01
US7780964B2 (en) 2010-08-24
MXPA06007190A (es) 2006-08-23
WO2005061545A3 (en) 2005-08-18
WO2005061544A3 (en) 2005-08-18
AU2004303585B2 (en) 2010-12-23
BRPI0417959A (pt) 2007-03-27
ES2330444T3 (es) 2009-12-10
JP2008504220A (ja) 2008-02-14
IL176206A0 (en) 2006-10-05
ATE440866T1 (de) 2009-09-15
KR20060129290A (ko) 2006-12-15
PL1711530T3 (pl) 2010-01-29
EP2213684A2 (en) 2010-08-04
AR048912A1 (es) 2006-06-14
DK1711530T3 (da) 2009-12-14
EP1711530A2 (en) 2006-10-18
KR101150548B1 (ko) 2012-07-06
DE602004022871D1 (de) 2009-10-08
JP4901480B2 (ja) 2012-03-21
IS2739B (is) 2011-06-15
WO2005061544A2 (en) 2005-07-07
JP2007537145A (ja) 2007-12-20
AU2004303585A1 (en) 2005-07-07
NO20062767L (no) 2006-09-20
RU2006123481A (ru) 2008-01-27
NZ548013A (en) 2009-04-30
US20070065430A1 (en) 2007-03-22
IL176206A (en) 2012-02-29
RU2362780C2 (ru) 2009-07-27
EP2213684A3 (en) 2011-05-18
CA2549956C (en) 2016-04-12
EP1711530B1 (en) 2009-08-26
TW200533680A (en) 2005-10-16
CY1110530T1 (el) 2015-04-29
US7988964B2 (en) 2011-08-02
SI1711530T1 (sl) 2010-01-29
US20110054149A1 (en) 2011-03-03
IS8506A (is) 2006-06-12
MA28289A1 (fr) 2006-11-01
CA2549956A1 (en) 2005-07-07
HK1100144A1 (en) 2007-09-07

Similar Documents

Publication Publication Date Title
HRP20090527T1 (en) Nogo-a neutralising immunoglobulins for treatment of neurological diseases
NZ604090A (en) Human anti-b7rp1 neutralizing antibodies
RS80704A (xx) ANTI-αvβ6 ANTITELA
SG151284A1 (en) Antibodies against ccr5 and uses thereof
NZ599196A (en) Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
RS51829B (sr) Ljudska antitela specifična za interleukin 15 (il-15)
RS54393B1 (en) HUMAN MONOCLONAL ANTIBODIES ON KINASE-1 SIMILAR TO ACTIVE RECEPTOR
ATE420660T1 (de) Antikörper gegen parath-hormon (pth) und ihre verwendungen
RS54452B1 (en) INGREDIENTS AND PROCEDURES FOR DIAGNOSIS AND TREATMENT OF CANCER
CU23292B7 (es) Anticuerpos monoclonales humanos de ctla-4
DE60333228D1 (de) Gegen den tumor nekrose faktor gerichtete antikörper und deren verwendungen
TW200634027A (en) Antibodies directed to angiopoietin-2 and uses thereof
GEP20074222B (en) Antibodies to cd40
NZ611859A (en) Antibody purification
ATE476994T1 (de) Antikörper gegen gpnmb und ihre verwendungen
MY148409A (en) Anti-mag antibodies
MX2009001110A (es) Anticuerpos monoclonales anti-il-6 y usos de los mismos.
WO2007120693A3 (en) Targeted binding agents directed to upar and uses thereof
TW200716182A (en) Antibodies directed to CD20 and uses thereof
IN2009KN02655A (xx)
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
WO2008112004A3 (en) ANTIBODIES DIRECTED TO αVβ6 AND USES THEREOF
SG155883A1 (en) Anti-cd3 antibodies and methods of use thereof
BR0112086A (pt) Anticorpos para mcp-1 humano
HK1071898A1 (en) Recombinant antibodies, and compositions and methods for making and using the same